Viking Therapeutic's (VKTX) Obesity Data Seen as 'Impressive'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
February 27, 2024 7:03 AM ESTStudy Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo
Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau ObservedÂ
VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate
Conference Call Scheduled for 8:00 a.m. ET Today
SAN DIEGO,... More
